Table 5 Analysis of baseline-adjusted AUC from 6 to 24 hours for all outcome measures
Placebo | IL-1Ra | ||||||
|---|---|---|---|---|---|---|---|
Mediator | Location | Raw | Adjusted | Raw | Adjusted | Difference | Pvalue |
IL-6 | CSF | 107.3 | 0.2 | 111.0 | −12.6 | 12.8 (−2.1 to 27.7) | 0.08 |
Plasma | 37.7 | −3.7 | 49.7 | −22.3 | 18.6 (−0.6 to 37.7) | 0.06 | |
IL-8 | CSF | 114.8 | 4.8 | 104.7 | −2.3 | 7.1 (−5.4 to 19.5) | 0.23 |
Plasma | 37.8 | 6.4 | 39.8 | −0.3 | 6.7 (−4.9 to 18.3) | 0.23 | |
IL-10 | CSF | 14.6 | −6.3 | 25.0 | −8.1 | 1.8 (−8.6 to 12.2) | 0.70 |
Plasma | 6.7 | 0.5 | 9.1 | −17.1 | 17.6 (4.3 to 30.9) | 0.01 | |
MCP-1 | CSF | 139.8 | 1.5 | 145.4 | −4.0 | 5.5 (−3.9 to 15.0) | 0.22 |
Plasma | 68.7 | −4.3 | 79.2 | −4.0 | −0.3 (−14.0 to 13.3) | 0.96 | |
CRP | Plasma | 65.2 | −1.6 | 84.5 | −0.5 | −1.1 (−10.3 to 8.1) | 0.79 |